Cosentyx (secukinumab) Please rate this page (bottom of page)

Share Button

This page contains a brief description that does not cover the medication. For more information read the review in Felleskatalogen.no for the respective drug.

Definition

The active substance is secukinumab which blocks IL-17 in the immune system and thus reduces rheumatic inflammation. Cosentyx is given as an injection under the skin (subcutaneously). The dose is 150-300mg subcutaneously monthly, often with more frequent dosing during the first few weeks of treatment and depending on the disease being treated.

Indications

Cosentyx is not the first treatment choice

Dosage

Side effects

Immunosuppressive treatment increases the risk of infection. More about side effects, precautions here (the Norwegian "Felleskatalogen")

Prescription

Patient information

Literature

Medications, BINDEVEVSSYKDOMMER.no


This page has had 1 visits today

Please rate this page